Amoxicillin/cefazolin, an alternative to amoxicillin/ceftriaxone against endocarditis associated E. faecalis ? An in vitro response. ( Peiffer-Smadja N. et al. )

In vitro bactericidal activity of amoxicillin combined with different cephalosporins against endocarditis-associated Enterococcus faecalis clinical isolates.

| Dr Jean-Pierre Bru

Synergy between third-generation cephalosporins (TGCs) and ampicillin was discovered in 1995 by Mainardi et al. and then confirmed in many … Suite  

Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia. Results of a phase 3 trial. ( Kollef MH. et al. )

Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.

| Dr Jean-Pierre Bru

This randomised, controlled, double-blind, non-inferiority trial was conducted at 263 hospitals in 34 countries. Eligible patients were adults, undergoing mechanical … Suite  

Evaluation of a molecular point-of-care testing for viral and atypical pathogens in lower respiratory tract infection: results of a randomized clinical trial ( D. Shengchen et al )

Evaluation of a molecular point-of-care testing for viral and atypical pathogens on intravenous antibiotic duration in hospitalized adults with lower respiratory tract infection: a randomized clinical trial

| Dr Jean-Pierre Bru

The aim of this study (conducted in Beijing) was to evaluate whether combination of point-of-care test (POCT) and routine real-time … Suite  

Treatment of Mycoplasma genitalium infection: efficacy of a resistance-guided strategy using doxycycline-moxifloxacin or doxycycline-azithromycin. ( Durukan D. et al. )

Resistance-guided antimicrobial therapy using doxycycline-moxifloxacin and doxycycline-2.5g azithromycin for the treatment of Mycoplasma genitalium infection: efficacy and tolerability.

| Dr Jean-Pierre Bru

Macrolide-resistance in Mycoplasma genitalium (MG) exceeds 50% in many regions and quinolone-resistance is increasing. The aim of the study was … Suite  

Ceftazidime-avibactam: monotherapy or combination therapy to treat carbapenem resistant gram-negative infections ? ( Onorato L. et al. )

Efficacy of ceftazidime-avibactam in monotherapy or combination therapy against carbapenem resistant gram negative organisms: a meta-analysis

| Dr Jean-Pierre Bru

Ceftazidime/avibactam, display in vitro activity against strains producing class-A-carbapenemases, including Klebsiella pneumoniae (KPC), as well as some class-D-carbapenemases, Some recent … Suite